Holdings announced that an abstract on updated clinical data from its Phase 1/2 clinical study conducted in the ...

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with ...

Investing.com -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) stock rose 2.4% following the announcement that an abstract on its CRB-701 clinical study has been accepted for presentation at the ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising ...

Ideaya Biosciences (IDYA) and Jiangsu Hengrui Pharmaceuticals Co. announced the publication of an abstract for an oral presentation on IDE849 at ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human ...